REGENXBIO INC (RGNX)

US75901B1070 - Common Stock

7.62  +0.21 (+2.83%)

Premarket: 8.08 +0.46 (+6.04%)

REGENXBIO INC

NASDAQ:RGNX (12/20/2024, 8:00:01 PM)

Premarket: 8.08 +0.46 (+6.04%)

7.62

+0.21 (+2.83%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%17.02%
Sales Q2Q%-16.31%
CRS5.52
6 Month-36.61%
Overview
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Ins Owners7.15%
Inst Owners92.41%
Market Cap377.57M
Shares49.55M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts84.21
Short Float %11.52%
Short Ratio5.93
IPO09-17 2015-09-17
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RGNX Daily chart

Company Profile

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 344 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The firm is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Company Info

REGENXBIO INC

9804 Medical Center Drive

Rockville MARYLAND 20850

P: 12405528181

CEO: Kenneth T. Mills

Employees: 344

Website: https://regenxbio.com/

RGNX News

News Image17 days ago - Investor's Business DailyWorkday, Apollo Global To Join S&P 500 Index In Quarterly Balance

They'll join the index before the open on Dec. 23 as part of a quarterly rebalance.

News Imagea month ago - REGENXBIO Inc.REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is...

News Imagea month ago - REGENXBIO Inc.REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE® pivotal program and new clinical...

News Image2 months ago - REGENXBIO Inc.REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this...

News Image2 months ago - REGENXBIO Inc.REGENXBIO to Participate in Upcoming Investor Conferences

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: UBS Global Healthcare Conference...

News Image2 months ago - Market News VideoOversold Conditions For REGENXBIO (RGNX)

RGNX Twits

Here you can normally see the latest stock twits on RGNX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example